Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of “Hold” by Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned an average recommendation of “Hold” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $19.00.

ENTA has been the subject of several research analyst reports. JMP Securities lowered their price objective on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 7th. StockNews.com upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Finally, HC Wainwright lowered their price target on shares of Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, May 7th.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $13.68 on Thursday. Enanta Pharmaceuticals has a one year low of $8.08 and a one year high of $20.18. The company has a market cap of $289.74 million, a P/E ratio of -2.19 and a beta of 0.60. The firm has a 50 day simple moving average of $12.77 and a two-hundred day simple moving average of $13.13.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.21). Enanta Pharmaceuticals had a negative net margin of 180.76% and a negative return on equity of 64.85%. The firm had revenue of $17.05 million for the quarter, compared to analyst estimates of $16.47 million. On average, analysts expect that Enanta Pharmaceuticals will post -5.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Tara Lynn Kieffer sold 7,266 shares of the business’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $12.33, for a total value of $89,589.78. Following the sale, the insider now owns 32,341 shares of the company’s stock, valued at $398,764.53. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 13.64% of the stock is currently owned by insiders.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Farallon Capital Management LLC boosted its position in Enanta Pharmaceuticals by 3.5% during the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after acquiring an additional 70,000 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Enanta Pharmaceuticals by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after purchasing an additional 134,292 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Enanta Pharmaceuticals by 1.3% during the 1st quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock worth $14,906,000 after purchasing an additional 10,952 shares in the last quarter. Krensavage Asset Management LLC boosted its position in shares of Enanta Pharmaceuticals by 6.9% during the 3rd quarter. Krensavage Asset Management LLC now owns 735,103 shares of the biotechnology company’s stock worth $8,211,000 after purchasing an additional 47,490 shares in the last quarter. Finally, Federated Hermes Inc. bought a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth about $1,253,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.